Synthesis and structure-activity relationship of 4-quinolone-3-carboxylic acid based inhibitors of glycogen synthase kinase-3β

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 19, 2011, Pages 5948-5951

  Cociorva, Oana M ^a   Li, Bei ^a   Nomanbhoy, Tyzoon ^a   Li, Qiang ^a   Nakamura, Ayako ^b   Nakamura, Kai ^a   Nomura, Masahiro ^b   Okada, Kyoko ^b   Seto, Shigeki ^b   Yumoto, Kazuhiro ^b   Liyanage, Marek ^a   Zhang, Melissa C ^a   Aban, Arwin ^a   Leen, Brandon ^a   Szardenings, Anna Katrin ^a   Rosenblum, Jonathan S ^a   Kozarich, John W ^a   Kohno, Yasushi ^b   Shreder, Kevin R ^a  

^a ACTIVX BIOSCIENCES INC   (United States)

^b KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

3 Carboxylic acid; 4 Quinolone; Anti bacterial; GSK 3 inhibitor; Kinase profiling

Indexed keywords

ANTIINFECTIVE AGENT; BICYCLO COMPOUND; CARBOXYLIC ACID DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION;

4-QUINOLONES; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GLYCOGEN SYNTHASE KINASE 3; HIGH-THROUGHPUT SCREENING ASSAYS; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

BACTERIA (MICROORGANISMS);

EID: 80052598447     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.07.073     Document Type: Article

References (12)

1. L. Kim, and A.R. Kimmel Curr. Opin. Genet. Dev. 10 2000 508
2. M.P. Coghlan, A.A. Culbert, D.A. Cross, S.L. Corcoran, J.W. Yates, N.J. Pearce, O.L. Rausch, G.J. Murphy, P.S. Carter, L. Roxbee Cox, D. Mills, M.J. Brown, D. Haigh, R.W. Ward, D.G. Smith, K.J. Murray, A.D. Reith, and J.C. Holder Chem. Biol. 7 2000 793
3. R.V. Bhat, S.L. Budd Haeberlein, and J. Avila J. Neurochem. 89 2004 1313
4. S. Haq, G. Choukroun, Z.B. Kang, H. Ranu, T. Matsui, A. Rosenzweig, J.D. Molkentin, A. Alessandrini, J. Woodgett, R. Hajjar, A. Michael, and T. Force J. Cell Biol. 151 2000 117
5. R.G. Gentles, S. Hu, and G. Dubowchik Annu. Rep. Med. Chem. 44 2009 736
6. D.B. Moran, C.B. Ziegler, T.S. Dunne, A.K. Kuck, and Y. Lin J. Med. Chem. 32 1989 1313
7. A. De Sarro, and G. De Sarro Curr. Med. Chem. 8 2001 371
8. J.P. Sanchez, R.D. Gogliotti, J.M. Domagala, S.J. Gracheck, M.D. Huband, J.A. Sesnie, M.A. Cohen, and M.A. Shapiro J. Med. Chem. 38 1995 4478
9. Anti-bacterial activity was measured by determining MIC values using standard microdilution methods recommended by the Clinical and Laboratory Standards Institute with Mueller-Hinton Broth (Becton Dickinson; Cockeysville, MD). The MIC was defined as the lowest concentration of the compound that inhibited visible growth after incubation for 18 h at 35 °C. See: Wikler, M. A.; Cockerill, F. R., III; Bush, K.; Dudley, M. N.; Eliopoulos, G. M.; Hardy, D. J.; Hindler, J. F.; Patel, J. B.; Powell, M.; Turnidge, J. D.; Weinstein, M. P.; Zimmer, B. L.; Ferraro, M. J.; Swenson, J.M. in Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Eighth Edition. Clinical and Laboratory Standards Institute, 2009, M07-A8.
10. D. Bouzard, P. Di Cesare, M. Essiz, J.P. Jacquet, B. Ledoussal, P. Remuzon, R.E. Kessler, and J. Fung-Tomc J. Med. Chem. 35 1992 518
11. M.P. Patricelli, A.K. Szardenings, M. Liyanage, T.K. Nomanbhoy, M. Wu, H. Weissig, A. Aban, D. Chun, S. Tanner, and J.W. Kozarich Biochemistry 46 2007 350
12. M.P. Patricelli, T.K. Nomanbhoy, J. Wu, H. Brown, D. Zhou, J. Zhang, S. Jagannathan, A. Aban, E. Okerberg, C. Herring, B. Nordin, H. Weissig, Q. Yang, J.-D. Lee, N.S. Gray, and J.W. Kozarich Chem. Biol. 18 2011 699